112 related articles for article (PubMed ID: 27327536)
1. Is a second recombinant human thyrotropin stimulation test useful? The value of postsurgical undetectable stimulated thyroglobulin level at the time of remnant ablation on clinical outcome.
Prior-Sánchez I; Barrera Martín A; Moreno Ortega E; Vallejo Casas JA; Gálvez Moreno MÁ
Clin Endocrinol (Oxf); 2017 Jan; 86(1):97-107. PubMed ID: 27327536
[TBL] [Abstract][Full Text] [Related]
2. Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer.
Toubeau M; Touzery C; Arveux P; Chaplain G; Vaillant G; Berriolo A; Riedinger JM; Boichot C; Cochet A; Brunotte F
J Nucl Med; 2004 Jun; 45(6):988-94. PubMed ID: 15181134
[TBL] [Abstract][Full Text] [Related]
3. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
[TBL] [Abstract][Full Text] [Related]
4. Limited value of repeat recombinant human thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels.
Castagna MG; Brilli L; Pilli T; Montanaro A; Cipri C; Fioravanti C; Sestini F; Capezzone M; Pacini F
J Clin Endocrinol Metab; 2008 Jan; 93(1):76-81. PubMed ID: 17971424
[TBL] [Abstract][Full Text] [Related]
5. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
[TBL] [Abstract][Full Text] [Related]
6. Quantitative thyroglobulin response to radioactive iodine treatment in predicting radioactive iodine-refractory thyroid cancer with pulmonary metastasis.
Wang C; Zhang X; Li H; Li X; Lin Y
PLoS One; 2017; 12(7):e0179664. PubMed ID: 28704384
[TBL] [Abstract][Full Text] [Related]
7. Serum thyrotropin level of 30 μIU/mL is inadequate for preablative thyroglobulin to serve as a prognostic marker for differentiated thyroid cancer.
Zhao T; Liang J; Guo Z; Li J; Lin Y
Endocrine; 2016 Jul; 53(1):166-73. PubMed ID: 26782372
[TBL] [Abstract][Full Text] [Related]
8. Undetectable sensitive serum thyroglobulin (<0.1 ng/ml) in 163 patients with follicular cell-derived thyroid cancer: results of rhTSH stimulation and neck ultrasonography and long-term biochemical and clinical follow-up.
Chindris AM; Diehl NN; Crook JE; Fatourechi V; Smallridge RC
J Clin Endocrinol Metab; 2012 Aug; 97(8):2714-23. PubMed ID: 22639286
[TBL] [Abstract][Full Text] [Related]
9. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
Giovanella L; Ceriani L; Suriano S; Ghelfo A; Maffioli M
Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
[TBL] [Abstract][Full Text] [Related]
10. Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin.
Malandrino P; Latina A; Marescalco S; Spadaro A; Regalbuto C; Fulco RA; Scollo C; Vigneri R; Pellegriti G
J Clin Endocrinol Metab; 2011 Jun; 96(6):1703-9. PubMed ID: 21450986
[TBL] [Abstract][Full Text] [Related]
11. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures.
Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G
Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439
[TBL] [Abstract][Full Text] [Related]
12. Thyroglobulin levels measured at the time of remnant ablation to predict response to treatment in differentiated thyroid cancer after thyroid hormone withdrawal or recombinant human TSH.
Pitoia F; Abelleira E; Cross G
Endocrine; 2017 Jan; 55(1):200-208. PubMed ID: 27655291
[TBL] [Abstract][Full Text] [Related]
13. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
[TBL] [Abstract][Full Text] [Related]
14. On-levothyroxine measurement of thyroglobulin is not a reliable test for the follow-up of patients at high risk for remnant/recurrent differentiated thyroid carcinoma.
Gholamrezanezhad A; Saghari M; Mirpour S; Beiki D; Tarbiat A; Javan S; Abdollahzadeh J
Endokrynol Pol; 2007; 58(2):100-4. PubMed ID: 17578824
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.
Brassard M; Borget I; Edet-Sanson A; Giraudet AL; Mundler O; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Toubert ME; Torlontano M; Benhamou E; Schlumberger M;
J Clin Endocrinol Metab; 2011 May; 96(5):1352-9. PubMed ID: 21389143
[TBL] [Abstract][Full Text] [Related]
16. Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.
Schlumberger M; Hitzel A; Toubert ME; Corone C; Troalen F; Schlageter MH; Claustrat F; Koscielny S; Taieb D; Toubeau M; Bonichon F; Borson-Chazot F; Leenhardt L; Schvartz C; Dejax C; Brenot-Rossi I; Torlontano M; Tenenbaum F; Bardet S; Bussière F; Girard JJ; Morel O; Schneegans O; Schlienger JL; Prost A; So D; Archambeaud F; Ricard M; Benhamou E
J Clin Endocrinol Metab; 2007 Jul; 92(7):2487-95. PubMed ID: 17426102
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma.
Pacini F; Molinaro E; Castagna MG; Agate L; Elisei R; Ceccarelli C; Lippi F; Taddei D; Grasso L; Pinchera A
J Clin Endocrinol Metab; 2003 Aug; 88(8):3668-73. PubMed ID: 12915653
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution.
Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR
Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064
[TBL] [Abstract][Full Text] [Related]
19. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?
Flores-Rebollar A; Pérez-Díaz I; Lagunas-Bárcenas S; García-Martínez B; Rivera-Moscoso R; Fagundo-Sierra R
Acta Otorhinolaryngol Ital; 2018 Jun; 38(3):188-193. PubMed ID: 29984794
[TBL] [Abstract][Full Text] [Related]
20. Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma.
Vaisman A; Orlov S; Yip J; Hu C; Lim T; Dowar M; Freeman JL; Walfish PG
Head Neck; 2010 Jun; 32(6):689-98. PubMed ID: 20187016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
